References
- Cagney DN, Martin AM, Catalano PJ, Redig AJ, Lin NU, Lee EQ, et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: A population-based study. Neuro Oncol 20217; 19: 1511–21. doi: 10.1093/neuonc/nox077
- Graber JJ, Cobbs CS, Olson JJ. Congress of neurological surgeons systematic review and evidence-based guidelines on the use of stereotactic radiosurgery in the treatment of adults with metastatic brain tumors. Neurosurgery 2019; 84: E168–E170. doi: 10.1093/neuros/nyy543
- Han JH, Kim DG, Chung HT, Paek SH, Park CK, Jung HW. Radiosurgery for large brain metastases. Int J Radiat Oncol Biol Phys 2012; 83: 113–20. doi: 10.1016/j.ijrobp.2011.06.1965
- Arvold ND, Lee EQ, Mehta MP, Margolin K, Alexander BM, Lin NU, et al. Updates in the management of brain metastases 2016; Neuro Oncol 2016; 18: 1043–65. doi: 10.1093/neuonc/now127
- Devoid HM, McTyre ER, Page BR, Metheny-Barlow L, Ruiz J, Chan MD. Recent advances in radiosurgical management of brain metastases. Front Biosci 2016; 8: 203–14. doi: 10.2741/s458
- Milano MT, Chiang VLS, Soltys SG, Wang TJC, Lo SS, Brackett, et al. Executive summary from American Radium Society’s appropriate use criteria on neurocognition after stereotactic radiosurgery for multiple brain metastases. Neuro Oncol 2020; 22: 1728–41. doi: 10.1093/neuonc/noaa192
- Hasegawa T, Kato T, Yamamoto T, Iizuka H, Nishikawa T, Ito H, et al. Multisession gamma knife surgery for large brain metastases. J Neurooncol 2017; 131: 517–24. doi: 10.1007/s11060-016-2317-4
- Dohm AE, Hughes R, Wheless W, Lecompte M, Lanier C, Ruiz J. Surgical resection and postoperative radiosurgery versus staged radiosurgery for large brain metastases. J Neurooncol 2018; 140: 749–56. doi: 10.1007/s11060-018-03008-8
- Yomo S, Hayashi M, Nicholson C. A prospective pilot study of two-session Gamma Knife surgery for large metastatic brain tumors. J Neurooncol 2012; 109: 159–65. doi: 10.1007/s11060-012-0882-8
- Angelov L, Mohammadi AM, Bennett EE, Abbassy M, Elson P, Chao ST, et al. Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases ≥ 2 cm. J Neurosurg 2018; 129: 366–82. doi: 10.3171/2017.3.JNS162532
- Serizawa T, Higuchi Y, Yamamoto M, Matsunaga S, Nagano O, Sato Y, et al. Comparison of treatment results between 3- And 2-stage Gamma Knife radiosurgery for large brain metastases: A retrospective multi-institutional study. J Neurosurg 2018; 131: 227–37. doi: 10.3171/2018.4.JNS172596
- Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, et al. Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol 2022; 40: 492–516. doi: 10.1200/JCO.21.02314
- Lehrer EJ, Peterson JL, Zaorsky NG, Brown PD, Sahgal A, Chiang VL, et al. Single versus multifraction stereotactic radiosurgery for large brain metastases: An international meta-analysis of 24 trials. Int J Radiat Oncol Biol Phys 2019; 103: 618–30. doi: 10.1016/j.ijrobp.2018.10.038
- Pintea B, Baumert B, Kinfe TM, Gousias K, Parpaley Y, Boström JP. Early motor function after local treatment of brain metastases in the motor cortex region with stereotactic radiotherapy/radiosurgery or microsurgical resection: A retrospective study of two consecutive cohorts. Radiat Oncol 2017; 12: 177. doi: 10.1186/s13014-017-0917-6
- Loganadane G, Dhermain F, Louvel G, Kauv P, Deutsch E, Le Péchoux C, et al. Brain radiation necrosis: Current management with a focus on non-small cell lung cancer patients. Front Oncol 2018; 8: 336. doi: 10.3389/fonc.2018.00336
- Miller JA, Bennett EE, Xiao R, Kotecha R, Chao ST, Vogelbaum MA, et al. Association between radiation necrosis and tumor biology after stereotactic radiosurgery for brain metastasis. Int J Radiat Oncol Biol Phys 2016; 96: 1060–9. doi: 10.1016/j.ijrobp.2016.08.039
- Linskey ME, Andrews DW, Asher AL, Burri SH, Kondziolka D, Robinson PD, et al. The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96: 45–68. doi: 10.1007/s11060-009-0073-4
- Desai B, Rassam D, Ezeh P, et al. Phase III trial of PF-06439535 or bevacizumab-eu plus paclitaxel/carboplatin in NSCLC. J Thorac Oncol 2015; 10: S665.
- Tamura R, Tanaka T, Miyake K, Yoshida K, Sasaki H. Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response. Brain Tumor Pathol 2017; 34: 62–77. doi: 10.1007/s10014-017-0284-x
- Lubelski D, Abdullah KG, Weil RJ, Marko NF. Bevacizumab for radiation necrosis following treatment of high grade glioma: A systematic review of the literature. J Neurooncol 2013; 115: 317–22. doi: 10.1007/s11060-013-1233-0
- Delishaj D, Ursino S, Pasqualetti F, Cristaudo A, Cosottini M, Fabrini MG, et al. Bevacizumab for the treatment of radiation-induced cerebral necrosis: A systematic review of the literature. J Clin Med Res 2017; 9: 273–80. doi: 10.14740/jocmr2936e
- Alanin MC, Klausen C, Caye-Thomasen P, Thomsen C, Fugleholm K, Poulsgaard L, et al. Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 – a retrospective case series. Int J Neurosci 2016; 126: 1002–6. doi: 10.3109/00207454.2015.1092443
- Hawasli AH, Rubin JB, Tran DD, Adkins DR, Waheed S, Hullar TE, et al. Antiangiogenic agents for nonmalignant brain tumors. J Neurol Surg B Skull Base 2013; 74: 136–41. doi: 10.1055/s-0033-1338262
- Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, et al. Response assessment criteria for brain metastases: Proposal from the RANO group. Lancet Oncol 2015; 16: e270–e8. doi: 10.1016/S1470-2045(15)70057-4
- Kano H, Kondziolka D, Lobato-Polo J, Zorro O, Flickinger JC, Lunsford LD. T1/T2 matching to differentiate tumor growth from radiation effects after stereotactic radiosurgery. Neurosurgery 2010, 66: 486–91. doi: 10.1227/01.NEU.0000360391.35749.A5
- Minamimoto R, Saginoya T, Kondo C, Tomura N, Ito K, Matsuo Y, et al. Differentiation of brain tumor recurrence from post-radiotherapy necrosis with 11C-methionine PET: Visual assessment versus quantitative assessment. PLoS One 2015; 10: e0132515. doi: 10.1371/journal.pone.0132515
- Paternostro-Sluga T, Grim-Stieger M, Posch M, Schuhfried O, Vacariu G, Mittermaier C, et al. Reliability and validity of the Medical Research Council (MRC) scale and a modified scale for testing muscle strength in patients with radial palsy. J Rehabil Med 2008; 40: 665–71. doi: 10.2340/16501977-0235
- Hankemeier A, Rollnik JD. The Early Functional Abilities (EFA) scale to assess neurological and neurosurgical early rehabilitation patients. BMC Neurol 2015; 15: 207. doi: 10.1186/s12883-015-0469-z
- Yomo S, Hayashi M. A minimally invasive treatment option for large metastatic brain tumors: Long-term results of two-session Gamma Knife stereotactic radiosurgery. Radiat Oncol 2014; 9: 132. doi: 10.1186/1748-717X-9-132
- Damron EP, Dono A, Chafi H, Martir M, Yu TK, Khwaja S, et al. Metastatic neoplasm volume kinetics following 2-stage stereotactic radiosurgery. World Neurosurg 2022; 161: e210–e9. doi: 10.1016/j.wneu.2022.01.109
- Hori Y, Muhsen B, Joshi K, Wei W, Borghei-Razavi H, Chao S et al. The efficacy and safety of two-staged stereotactic radiosurgery for large posterior fossa metastases: post-treatment volumetric changes in tumor size, peri-tumoral edema, and fourth ventricle. Neuro Oncol 2020; 22 Suppl2: ii181. doi: 10.1093/neuonc/noaa215.756
- Ito D, Aoyagi K, Nagano O, Serizawa T, Iwadate Y, Higuchi Y. Comparison of two-stage Gamma Knife radiosurgery outcomes for large brain metastases among primary cancers. J Neurooncol 2020; 147: 237–46. doi: 10.1007/s11060-020-03421-y
- Cho A, Medvedeva K, Kranawetter B, Untersteiner H, Hirschmann D, Lepilina O, et al. How to dose-stage large or high-risk brain metastases: an alternative two-fraction radiosurgical treatment approach. J Neurosurg 2022; 137: 1666–75. doi: 10.3171/2022.2.JNS212440
- Li J, He J, Cai L, Lai M, Hu Q, Ren C, et al. Bevacizumab as a treatment for radiation necrosis following stereotactic radiosurgery for brain metastases: clinical and radiation dosimetric impacts. Ann Palliat Med 2021; 10: 2018–26. doi: 10.21037/apm-20-2417
- Erpolat OP, Demircan NV, Sarıbas GS, Kuzucu P, Senturk E, Elmas C, et al. A comparison of Ramipril and Bevacizumab to mitigate radiation-induced brain necrosis: An experimental study. World Neurosurg 2020; 144: e210–e20. doi: 10.1016/j.wneu.2020.08.081
- Ai B, Zhang L, Huang D, Chen J, Liu Z, Hu X, et al. Efficacy and safety of bevacizumab in advanced lung adenocarcinoma patients with stable disease after two cycles of first-line chemotherapy: A multicenter prospective cohort study. Thorac Cancer 2020; 11: 3641–4. doi: 10.1111/1759-7714.13687